Safety and Effectiveness of Tirzepatide in Solid-Organ Transplant Recipients.
作者信息
Sweiss Helen, Flores Ryan, Windler Samantha, Hall Reed, Bhayana Suverta, Patel Rupal, Long Christina
机构信息
Department of Pharmacotherapy & Pharmacy Services, University Health, San Antonio, TX.
University Health Transplant Institute, University Health, San Antonio, TX.
出版信息
Diabetes Spectr. 2025 Jun 13;38(3):368-371. doi: 10.2337/ds24-0071. eCollection 2025 Summer.
Abstract
摘要
相似文献
1
Safety and Effectiveness of Tirzepatide in Solid-Organ Transplant Recipients.
Diabetes Spectr. 2025 Jun 13;38(3):368-371. doi: 10.2337/ds24-0071. eCollection 2025 Summer.
2
Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
Transplant Cell Ther. 2024 Jan;30(1):73.e1-73.e12. doi: 10.1016/j.jtct.2023.05.018. Epub 2023 Jun 4.
3
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
4
Safety and Efficacy of Tirzepatide in Solid-Organ Transplant Recipients: Experience of a Quaternary Care Center in the Middle East.
Exp Clin Transplant. 2025 Jan;23(1):12-20. doi: 10.6002/ect.2024.0284.
5
Cancer risk in people living with HIV and solid organ transplant recipients: a systematic review and meta-analysis.
Lancet Oncol. 2024 Jul;25(7):933-944. doi: 10.1016/S1470-2045(24)00189-X.
6
Cancers with epidemiologic signatures of viral oncogenicity among immunocompromised populations in the United States.
J Natl Cancer Inst. 2024 Dec 1;116(12):1983-1991. doi: 10.1093/jnci/djae159.
7
Impact of antiviral prophylaxis on EBV viremia and posttransplant lymphoproliferative disorders in solid organ transplant recipients: a systematic review and meta-analysis.
Virol J. 2025 Jan 15;22(1):11. doi: 10.1186/s12985-025-02623-y.
8
Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review.
Transplant Rev (Orlando). 2023 Jan;37(1):100729. doi: 10.1016/j.trre.2022.100729. Epub 2022 Nov 4.
9
Combination of LED illumination and daylight photodynamic therapy for the treatment of actinic keratosis in solid organ transplant recipients: a prospective, randomized, comparative, intra-patient study.
J Dtsch Dermatol Ges. 2025 Jun;23(6):713-718. doi: 10.1111/ddg.15665. Epub 2025 Apr 14.
10
Severe maternal morbidity and risk of transplant rejection in pregnant patients with a history of solid-organ transplant.
Am J Obstet Gynecol MFM. 2025 Jul;7(7):101696. doi: 10.1016/j.ajogmf.2025.101696. Epub 2025 May 10.
本文引用的文献
1
International consensus on post-transplantation diabetes mellitus.
Nephrol Dial Transplant. 2024 Feb 28;39(3):531-549. doi: 10.1093/ndt/gfad258.
2
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.
Diabetes Care. 2024 Jan 1;47(Suppl 1):S158-S178. doi: 10.2337/dc24-S009.
3
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Diabetes Care. 2022 Nov 1;45(11):2753-2786. doi: 10.2337/dci22-0034.
4
Posttransplantation Diabetes Mellitus Among Solid Organ Recipients in a Danish Cohort.
Transpl Int. 2022 Apr 5;35:10352. doi: 10.3389/ti.2022.10352. eCollection 2022.
5
The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction.
Diabetes Metab Syndr Obes. 2022 Apr 5;15:1023-1030. doi: 10.2147/DMSO.S351982. eCollection 2022.
6
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18.
7
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Lancet. 2021 Aug 14;398(10300):583-598. doi: 10.1016/S0140-6736(21)01443-4. Epub 2021 Aug 6.
8
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Lancet. 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6. Epub 2021 Jun 27.
9
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25.
10
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Lancet. 2018 Nov 17;392(10160):2180-2193. doi: 10.1016/S0140-6736(18)32260-8. Epub 2018 Oct 4.
Zotero 插件